Navigation Links
CardioInsight Announces CE Mark Clearance and European Launch of the ECVUE™ Non-Invasive Electrocardiographic Mapping System
Date:11/30/2011

CLEVELAND, Nov. 30, 2011 /PRNewswire-USNewswire/ -- CardioInsight Technologies Inc., the leading developer of non-invasive electrocardiographic mapping technology, announced today CE Mark clearance and the European commercial launch of its ECVUESystem to aid in the diagnosis of cardiac arrhythmias. In conjunction with this commercial launch, CardioInsight announced that it has secured its first three clinical customers, which include Dr. Wyn Davies at St. Mary's Hospital in London, England, Dr. Heinz-Friedrich Pitschner at the Kerckhoff Heart and Lung Center in Bad Neuheim, Germany, and Dr. Michel Haissaguerre at Hopital Cardiologique du Haut–Leveque in Bordeaux, France.

(Logo: http://photos.prnewswire.com/prnh/20110531/DC10432LOGO)  

CardioInsight's patented ECVUE technology gathers electrical information from an electrode "vest" placed on a patient's body and combines the information with images from a CT scan to produce 3D "electrical maps" of the patient's heart. It is the first non-invasive, real-time, single beat, mapping solution to potentially improve the diagnosis and treatment of electrical abnormalities of the heart, including cardiac arrhythmias and congestive heart failure.

"Receiving the CE Mark is a significant milestone, and validates the ECVUE technology's evolution to a commercial-ready product," said Chief Executive Officer Steve Arless. "We are excited to have attracted the interest of world-renowned clinicians as our first commercial customers, and are eager to continue to validate the technology's unique clinical value proposition."

To date, CardioInsight has completed more than 390 patient studies at leading clinical centers in the United States and Europe. These studies address a broad variety of cardiac arrhythmias, as well as cardiac resynchronization therapy for congestive heart failure, demonstrating the unique cli
'/>"/>

SOURCE CardioInsight Technologies Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... , August 19, 2014 Elbit ... EMITF ) announced today that Elbit Medical Technologies ... Company in which it holds approximately 86% of the ... Cell Ltd., in which Elbit Medical holds approximately 30.8% ... majority of Gamida Cell,s shareholders (including Elbit Medical), signed ...
(Date:8/18/2014)... , August 19, 2014 ... cell expansion technologies and therapeutic products, announced today that it ... Pharma AG  ( " Novartis " ... $35 million in Gamida Cell and in return will receive ... The option is exercisable for a limited period of time ...
(Date:8/18/2014)... YORK , Aug. 18, 2014 /PRNewswire/ ... research report is available in its catalogue: ... Biopharmaceutical Markets ... be categorized into three types: chromatography, membranes/filters ... products is increasing and fueling growth of ...
Breaking Medicine Technology:Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 2Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 4Bioseparation Systems for Global Biopharmaceutical Markets 2Bioseparation Systems for Global Biopharmaceutical Markets 3Bioseparation Systems for Global Biopharmaceutical Markets 4Bioseparation Systems for Global Biopharmaceutical Markets 5Bioseparation Systems for Global Biopharmaceutical Markets 6Bioseparation Systems for Global Biopharmaceutical Markets 7Bioseparation Systems for Global Biopharmaceutical Markets 8Bioseparation Systems for Global Biopharmaceutical Markets 9Bioseparation Systems for Global Biopharmaceutical Markets 10Bioseparation Systems for Global Biopharmaceutical Markets 11Bioseparation Systems for Global Biopharmaceutical Markets 12
... Cempra Pharmaceuticals today announced results from its Phase ... tolerability of oral administration of our fourth generation ... with oral levofloxacin for the treatment of community-acquired ... CEM-101 demonstrated efficacy comparable to levofloxacin and a ...
... Sept. 15, 2011 Reportlinker.com announces that ... in its catalogue: Global ... http://www.reportlinker.com/p0240543/Global-Blood-Glucose-Test-Strips-Market-2010-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... Test Strips market to grow at a ...
Cached Medicine Technology:Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP) 2Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP) 3Global Blood Glucose Test Strips Market 2010-2014 2
(Date:8/19/2014)... Horizon Blue Cross Blue Shield of New Jersey ... again teaming up during The Barclays at The Ridgewood ... Challenge, and Horizon BCBSNJ will be getting spectators into the ... their own. , Horizon BCBSNJ, the official health care sponsor ... donation to the New Jersey Golf Foundation, an organization that ...
(Date:8/19/2014)... NY (PRWEB) August 19, 2014 ... were named the winner of the 2014 Independent ... took home the first place position in “Product ... marketplace specially-formatted eyeliner, which also includes a lash ... black color, plus lash-boosting technology. , ...
(Date:8/19/2014)... August 19, 2014 Following the completion of ... Hyatt Tampa Bay is proud to debut the highly ... project included a full revamp of all public spaces to ... rooms and suites, an all-new dining experience at 1823 Kitchen ... lobby. , With the introduction of 1823 Kitchen and Bar, ...
(Date:8/19/2014)... Philadelphia, PA, August 19, 2014 Warfarin, the ... competition from new options in the anticoagulant drug ... study documents the rapid adoption of these novel ... NOACs accounted for 62% of all new anticoagulant ... drug costs. Findings are published in The ...
(Date:8/19/2014)... Title Boxing Club Cool Springs is now open. ... away prizes – including an entire year's membership. Sweepstakes ... and click on the “Hit It Hard” Sweepstakes. Once ... enters, you will receive an additional chance to win. ... take advantage of the “Pre-Opening Special” which Includes a ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 3Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 4Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:Grand Hyatt Tampa Bay Hotel Unveils the Finishing Touches of Its $20 Million Makeover 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 3Health News:Title Boxing Club Cool Springs is Officially Open 2
... CBM ) reports fourth quarter and full year 2008 results ... , Sales increased 0.8% compared ... the impact of foreign currency. Reported sales declined by 6.6% ... Adjusted EBITDA (see attached table) was $10.7 ...
... New Product Development, Marketing and InnovationBEDFORD, Mass., Feb. ... and produced by Insulet Corporation (Nasdaq: ... for the prestigious 2009 Edison Best New Product ... accolades honoring excellence in new product development, marketing, ...
... to better diagnosis, treatment for heart patients , , WEDNESDAY, ... called contrast echocardiography had a significant impact on the ... a new study found. , Echocardiography bounces sound waves ... the moving heart. If that image isn,t clear enough, ...
... than $1000. , ... Eagan, MN (Vocus) February 11, 2009 -- Employees ... United Way of Northeastern Minnesota. A company cookbook was created and ... Iowa. More than 200 cookbooks were sold. , , , ...
... Doctors with Plastic Surgery Services of Fredericksburg ... area to offer LATISSE(TM), the new FDA-approved prescription ... darker, fuller and longer. LATISSE,s maker, Allergan, ... BOTOX(R) and Juvederm(TM). The active ingredient in LATISSE(TM) ...
... doctors at high-volume hospitals do best, study finds , , ... a person surviving a heart attack roughly double ... and facility experienced in the use of angioplasty and ... percutaneous coronary interevention (PCI), which uses angioplasty and a ...
Cached Medicine News:Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 2Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 3Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 4Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 5Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 6Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 7Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 8Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 9Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 10Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 11Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 12Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 13Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 14Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 15Health News:OmniPod(R) Insulin Management System Selected as a Finalist for the 2009 Edison Best New Product Awards(TM) 2Health News:OmniPod(R) Insulin Management System Selected as a Finalist for the 2009 Edison Best New Product Awards(TM) 3Health News:Study Brings Value of Echocardiography Into Focus 2Health News:Company Cookbook Proceeds to Benefit United Way of Northeastern Minnesota 2Health News:Long and Lovely Lashes by LATISSE(TM) Now Available Through Plastic Surgery Services of Fredericksburg 2Health News:Experience Brings Better Angioplasty Outcomes 2
... EDTA K2 / gel tubes are ... for molecular diagnostics and for viral ... whole blood remain stable at room ... For optimal results, it is recommended ...
... offered as either EDTA K2 or ... calcium ions and therefore blocks the ... in an EDTA anticoagulated blood sample ... hours. EDTA tubes are for the ...
... is a ubiquitous enzyme that catalyzes ... is also the specific protein that ... immunofluorescence (EMA) tests (Bio-Rad catalog number ... serologic tests are highly sensitive and ...
... blood oximeters provide cardiologists with critical ... a patient's blood. The Oxicom series ... over a half-million saturation samples measured ... cost-effective oxygen saturation readings in less ...
Medicine Products: